044IC - AUA Guidelines on Advanced Prostate Cancer

Saturday, April 29, 2023

4:00 PM – 6:00 PM CST

Location: S103B

Instructional Course Director(s)

Michael Cookson, MD (he/him/his)

Professor and Chair
University of Oklahoma

Instructional Course Faculty(s)

DJ

David Jarrard, MD (he/him/his)

Professor
University of Wisconsin
Adam Kibel, MD (he/him/his)

Elliott Carr Cutler Professor of Surgery, Chair, Department of Urology
Mass General Brigham, Harvard University
WL

William Lowrance, MD, MPH

Urology Specialist

Course Description: Incorporating the most updated AUA/ASTRO/SUO APC Guidelines, this course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic hormone sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC). The course will include germline testing, PSMA positron emission tomography imaging, and the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. The role of treatment intensification in mHSPC will be discussed. The course will also cover nonmetastatic CRPC and treatment for metastatic CRPC. The use of sequencing, combination therapy, germline and somatic testing, precision medicine with PARP inhibitors and theranostics will also be discussed. The course will also cover emerging salvage therapies for CRPC.

Learning Objectives:

Identify appropriate use of genetic testing and genetic counseling.
Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy.
Discuss treatment intensification in mHSPC.
Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing.